ArticleStem cell research & therapy2020
Human placenta-derived mesenchymal stem cells stimulate ovarian function via miR-145 and bone morphogenetic protein signaling in aged rats.
Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Mesenchymal stem cell therapy for premature ovarian insufficiency: progress and challenges.Journal of ovarian research · 2026Review
- Maternal plasma microRNAs as potential biomarkers for triaging pregnancies of unknown location and ectopic pregnancy diagnosis.Non-coding RNA research · 2025Article
- Precision medicine in premature ovarian insufficiency: a focus on the precision therapeutic strategies for mesenchymal stem cells.Stem cell research & therapy · 2025Review
- Preservation of ovarian function using human pluripotent stem cell-derived mesenchymal progenitor cells.Clinical and experimental reproductive medicine · 2025Article
- Use of placental-derived mesenchymal stem cells to restore ovarian function and metabolic profile in a rat model of the polycystic ovarian syndrome.BMC endocrine disorders · 2024Article
- Protective role of stem cells in POI: Current status and mechanism of action, a review article.Heliyon · 2024Review
- Mesenchymal stem cell-derived apoptotic vesicles ameliorate impaired ovarian folliculogenesis in polycystic ovary syndrome and ovarian aging by targeting WNT signaling.Theranostics · 2024Article
- The stromal microenvironment and ovarian aging: mechanisms and therapeutic opportunities.Journal of ovarian research · 2023Review
- Multipotent fetal stem cells in reproductive biology research.Stem cell research & therapy · 2023Review
- Metabolic Mechanisms and Potential Therapeutic Targets for Prevention of Ovarian Aging: Data from Up-to-Date Experimental Studies.International journal of molecular sciences · 2023Review
- Bone Marrow Mesenchymal Stem Cells Reversed Ovarian Aging-related m6A RNA Methylation Modification Profile in Aged Granulosa Cells.Stem cell reviews and reports · 2023Article
- Use of mesenchymal stem cells to enhance or restore fertility potential: a systematic review of available experimental strategies.Human reproduction open · 2023Review
- Effects of human placenta cryopreservation on molecular characteristics of placental mesenchymal stromal cells.Frontiers in bioengineering and biotechnology · 2023Article
- Aged mice ovaries harbor stem cells and germ cell nests but fail to form follicles.Journal of ovarian research · 2022Article
- Metabolic Rewiring by Human Placenta-Derived Mesenchymal Stem Cell Therapy Promotes Rejuvenation in Aged Female Rats.International journal of molecular sciences · 2022Article
- MiR-191-5p is upregulated in culture media of implanted human embryo on day fifth of development.Reproductive biology and endocrinology : RB&E · 2021Article
- Is It Possible to Treat Infertility with Stem Cells?Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Association of microRNAs With Embryo Development and Fertilization in Women Undergoing Subfertility Treatments: A Pilot Study.Frontiers in reproductive health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAging has detrimental effects on the ovary, such as a progressive reduction in fertility and decreased hormone production, that greatly reduce the quality of life of women. Thus, the current study was undertaken to investigate whether human placenta-derived mesenchymal stem cell (hPD-MSC) treatment can restore the decreases in folliculogenesis and ovarian function that occur with aging.
methodsAcclimatized 52-week-old female SD rats were randomly divided into four groups: single hPD-MSC (5 × 10
resultsWe observed that multiple transplantations of hPD-MSCs more effectively promoted primordial follicle activation and ovarian hormone (E
conclusionsOur study verified that multiple intravenous injections of hPD-MSCs led to improved ovarian function via miR-145-5p and BMP-SMAD signaling and proposed the future therapeutic potential of hPD-MSCs to promote ovarian function in women at advanced age to improve their quality of life during climacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.